Tighter safeguards proposed for high-risk clinical trials
July 26, 2006Research and Development
The expert group set up by the MHRA in the wake of the disastrous Northwick Park clinical trial has made …
Novartis speeds up Tasigna programme
July 25, 2006Sales and Marketing
Novartis' new cancer drug will be submitted earlier than expected for European and US approval after showing positive results in …
Are you ready to become an interim manager?
July 25, 2006Business Services interim management, recruitment
The last few years have seen both dramatic and rapid changes in the adoption of interim management in the life …
Use your intelligence to watch the competition
July 25, 2006Research and Development, Sales and Marketing market research
One of the reasons the executives of ill-fated US energy group Enron were for a while 'the smartest guys in …
NHS allergy services criticised
July 21, 2006People with allergies often feel let down by NHS services with patient groups expected to make up shortfalls, according to …
Roche surges on cancer drug sales
July 21, 2006Sales and Marketing
Strong demand for Roche's cancer portfolio helped the Swiss pharma company grow at more than three times the industry rate …
Patient dies after winning access to cancer drug
July 21, 2006A Lancashire man with terminal lung cancer has died just days after winning a court battle to force his PCT …
Pfizer sets out on $17 billion acquisition trail
July 21, 2006Sales and Marketing Pfizer
Pfizer, the world's biggest pharmaceutical company, has earmarked $17 billion to spend on new products and technologies over the next …
UK uptake of vaccine boosts Wyeth
July 21, 2006Sales and Marketing
The long-awaited addition of Wyeth Prevnar to the UK's vaccination programme has helped the company increase revenues in the second …
Xeloda filed for advanced stomach cancer
July 21, 2006Sales and Marketing
Roche has filed its drug Xeloda to treat patients with advanced stomach cancer, the second biggest cancer killer worldwide.The oral …
New licence allows patients to switch to Arimidex
July 14, 2006Sales and Marketing
AstraZeneca has gained a new licence for its breast cancer drug Arimidex to allow patients to switch from tamoxifen after …
Tysabri returns with new safety precautions
July 13, 2006Sales and Marketing
Multiple sclerosis drug Tysabri is set to be re-launched after overcoming serious concerns about its safety.Co-marketed by Elan and Biogen …
AstraZeneca and Abbott to develop combined lipid-targeting drug
July 13, 2006Sales and Marketing
AstraZeneca and Abbott are to co-develop and market a combination treatment that will target three important blood lipids in one …
PCT fights Herceptin approval
July 12, 2006A primary care trust has appealed against the NICE recommendation of Herceptin, apparently challenging how many women should receive the …
MabThera approved for rheumatoid arthritis
July 11, 2006Sales and Marketing
Roche's blockbuster cancer drug MabThera has gained European marketing approval to treat rheumatoid arthritis.First launched in 1997, MabThera (rituximab) made …
Avastin filed for breast cancer treatment
July 10, 2006Sales and Marketing
Roche's Avastin could be licensed to treat advanced breast cancer in Europe by early 2007, following its filing with regulator …
Lilly to close UK manufacturing site but retains R&D operations
July 7, 2006Manufacturing and Production
Pharmaceutical company Lilly is to close its UK manufacturing facility in Basingstoke with as many as 300 employees expected to …
Anti-smoking ad lights up Best of Health awards
July 7, 2006Medical Communications Best of Health, advertising, awards, events
Clear Marketing Communications has taken the top prize at the 2006 Best of Health Awards with a striking advert highlighting …
Work progressing on Scotland’s ‘unique’ biotech campus
July 7, 2006Research and Development
Plans to make Scotland a major centre for innovative biotech and pharmaceutical research are progressing, with a major new centre …
Company behind Northwick Park trial files for insolvency
July 7, 2006Sales and Marketing
The pharmaceutical company behind TGN 1412, the drug which caused near-fatal reactions in six clinical trials volunteers at Northwick Park, …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
